drugset / Trial / NCT06940141
Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 2, randomized, multicenter study in adult and adolescent participants with asthma and type 2 inflammation
Timeline
- Start
- 2025-08-08
- Primary completion
- 2026-07-13
- Completion
- 2026-08-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rademikibart | Monoclonal antibody | 600 mg | Subcutaneous |